Two Schemes Response in Multiple Myeloma

RecruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

November 20, 2023

Primary Completion Date

March 20, 2024

Study Completion Date

October 30, 2024

Conditions

Response, Acute PhaseSurvivorship

Interventions

DRUG

Bortezomib

Bortezomib 1.3mg/m2 SC on days 1,4, 8,11 to the TD scheme for a total of 6 treatment cycles (14,15) (VTD)

Trial Locations (1)

RECRUITING

Hospital General de Mexico Dr. Eduardo Liceaga, Mexico City

All Listed Sponsors

lead

Hospital General de Mexico

OTHER_GOV